- Home
- MIST vs PBYI Comparison
MIST vs PBYI Comparison
Compare MIST & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- PBYI
- Stock Information
- Founded
- MIST 2003
- PBYI 2010
- Country
- MIST Canada
- PBYI United States
- Employees
- MIST N/A
- PBYI N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- PBYI Health Care
- Exchange
- MIST Nasdaq
- PBYI Nasdaq
- Market Cap
- MIST 145.3M
- PBYI 171.7M
- IPO Year
- MIST N/A
- PBYI N/A
- Fundamental
- Price
- MIST $1.97
- PBYI $4.64
- Analyst Decision
- MIST Strong Buy
- PBYI Strong Buy
- Analyst Count
- MIST 3
- PBYI 1
- Target Price
- MIST $6.33
- PBYI $7.00
- AVG Volume (30 Days)
- MIST 1.2M
- PBYI 648.1K
- Earning Date
- MIST 11-11-2025
- PBYI 11-06-2025
- Dividend Yield
- MIST N/A
- PBYI N/A
- EPS Growth
- MIST N/A
- PBYI 434.29
- EPS
- MIST N/A
- PBYI 0.97
- Revenue
- MIST N/A
- PBYI $238,062,000.00
- Revenue This Year
- MIST N/A
- PBYI N/A
- Revenue Next Year
- MIST N/A
- PBYI N/A
- P/E Ratio
- MIST N/A
- PBYI $4.76
- Revenue Growth
- MIST N/A
- PBYI 8.63
- 52 Week Low
- MIST $0.63
- PBYI $2.32
- 52 Week High
- MIST $2.75
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- MIST 67.34
- PBYI 49.99
- Support Level
- MIST $1.75
- PBYI $4.49
- Resistance Level
- MIST $1.83
- PBYI $5.22
- Average True Range (ATR)
- MIST 0.09
- PBYI 0.26
- MACD
- MIST 0.02
- PBYI -0.12
- Stochastic Oscillator
- MIST 79.49
- PBYI 22.33
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.